B
Barbara Roniker
Researcher at Pharmacia
Publications - 36
Citations - 7286
Barbara Roniker is an academic researcher from Pharmacia. The author has contributed to research in topics: Eplerenone & Aldosterone. The author has an hindex of 17, co-authored 36 publications receiving 6973 citations. Previous affiliations of Barbara Roniker include National Cheng Kung University & Pfizer.
Papers
More filters
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Bertram Pitt,Nathaniel Reichek,Roland Willenbrock,Faiez Zannad,Robert A. Phillips,Barbara Roniker,Jay Kleiman,Scott Krause,Daniel Burns,Gordon H. Williams +9 more
TL;DR: The combination of eplerenone and enalapril was more effective in reducing LV mass and systolic blood pressure than eplererenone alone and the combination was as effective as en alapril in LVH regression and blood pressure control.
Journal ArticleDOI
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
TL;DR: Eplerenone doses of 50 to 400 mg once daily are well tolerated and effective in reducing BP in patients with mild-to-moderate hypertension during a 24-h period.
Journal ArticleDOI
The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction
Bertram Pitt,Bertram Pitt,Bertram Pitt,Gordon H. Williams,Gordon H. Williams,Gordon H. Williams,Willem Remme,Willem Remme,Willem Remme,Felipe Martinez,Felipe Martinez,Felipe Martinez,Jose Lopez-Sendon,Jose Lopez-Sendon,Jose Lopez-Sendon,Faiez Zannad,Faiez Zannad,Faiez Zannad,James D. Neaton,James D. Neaton,James D. Neaton,Barbara Roniker,Barbara Roniker,Barbara Roniker,Steve Hurley,Steve Hurley,Steve Hurley,Dan Burns,Dan Burns,Dan Burns,Richard Bittman,Richard Bittman,Richard Bittman,Jay H. Kleiman,Jay H. Kleiman,Jay H. Kleiman +35 more
TL;DR: If the hypothesis being tested in the EPHESUS trial proves correct, eplerenone has the potential to be used in a broad population to prevent progressive left ventricular remodeling, ventricular fibrosis, malignant arrhythmias, non-fatal AMI, and sudden cardiac death.
Journal ArticleDOI
Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension
William B. White,Daniel Duprez,Richard St Hillaire,Scott Krause,Barbara Roniker,Janice Kuse-Hamilton,Michael A. Weber +6 more
TL;DR: Eplerenone was as effective as amlodipine in lowering systolic BP and pulse pressure as well as pulse wave velocity in older patients with widened pulse pressure hypertension and reduced microalbuminuria to a greater extent in this older patient group.